| Literature DB >> 35873162 |
Melissa Depypere1,2, Jonathan Sliepen3, Jolien Onsea4,5, Yves Debaveye6, Geertje A M Govaert7, Frank F A IJpma3, Werner Zimmerli8, Willem-Jan Metsemakers4,5.
Abstract
Purpose: Fracture-related infection (FRI) is an important complication related to orthopaedic trauma. Although the scientific interest with respect to the diagnosis and treatment of FRI is increasing, data on the microbiological epidemiology remains limited. Therefore, the primary aim of this study was to evaluate the microbiological epidemiology related to FRI, including the association with clinical symptoms and antimicrobial susceptibility data. The secondary aim was to analyze whether there was a relationship between the time to onset of infection and the microbiological etiology of FRI.Entities:
Keywords: antibiotic resistance; fracture; fracture-related infection; infection; microbiology
Mesh:
Substances:
Year: 2022 PMID: 35873162 PMCID: PMC9300981 DOI: 10.3389/fcimb.2022.934485
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Population characteristics and clinical presentation according to time after device implantation.
| Characteristics | Early FRI (<14 days) n = 34 (%) | Delayed FRI (14-70 days) n = 74 (%) | Late FRI (>70 days) n = 86 (%) | p-value (early vs delayed vs late) |
|---|---|---|---|---|
|
| 0.534 | |||
| Male | 19 (57.6) | 50 (67.6) | 57 (68.6) | |
| Female | 14 (42.4) | 24 (32.4) | 27 (32.4) | |
|
| 61 (44–70) | 52 (41-70) | 55 (43-67) | 0.725 |
|
| 25.7 (23.2-30.3) | 25.4 (23.8-28.4) | 26.4 (22.7-30.2) | 0.637 |
|
| 0.726 | |||
| I | 4 (12.1) | 14 (18.9) | 13 (15.5) | |
| II | 18 (54.5) | 34 (45.9) | 45 (53.6) | |
| III | 9 (27.2) | 24 (32.4) | 25 (29.8) | |
| IV | 2 (6.0) | 2 (2.7) | 1 (1.2) | |
|
| ||||
|
| ||||
| Clavicle | 0 (0.0) | 10 (13.5)* | 3 (3.5) |
|
| Humerus | 5 (14.7) | 11 (14.9) | 8 (9.3) | 0.511 |
| Forearm | 0 (0.0) | 6 (8.1) | 10 (11.6) | 0.094 |
| Femur | 7 (20.6) | 6 (8.1)* | 23 (26.7)* |
|
| Tibia | 12 (35.3) | 15 (20.3) | 19 (22.1) | 0.209 |
| Fibula | 3 (8.8) | 9 (12.2) | 6 (7.0) | 0.527 |
| Ankle | 4 (11.8) | 12 (16.2) | 14 (16.3) | 0.806 |
| Calcaneus | 0 (0.0) | 2 (2.7) | 2 (2.3) | 1.000 |
| Patella | 2 (5.9) | 2 (2.7) | 1 (1.2) | 0.262 |
| Scapula | 1 (2.9) | 0 (0.0) | 0 (0.0) | 0.175 |
| Sternum | 0 (0.0) | 1 (1.4) | 0 (0.0) | 0.557 |
|
| 0.067 | |||
| Closed | 21 (61.8) | 61 (82.4) | 64 (74.4) | |
| Open | 13 (38.2) | 13 (17.6) | 22 (25.6) | |
|
| 0.682 | |||
| 1 | 4 (11.8) | 3 (4.1) | 7 (8.1) | |
| 2 | 4 (11.8) | 6 (8.1) | 11 (12.8) | |
| 3 | 5 (14.7) | 4 (5.4) | 4 (4.7) | |
|
| ||||
| Fistula | 7 (20.6) | 16 (21.6) | 19 (22.1) | 0.984 |
| Wound breakdown | 8 (23.5) | 27 (36.5) | 17 (19.8) | 0.053 |
| Purulent discharge/pus | 18 (52.9) | 35 (47.3) | 30 (34.9) | 0.120 |
| Redness | 19 (55.9) | 38 (51.4) | 36 (41.9) | 0.290 |
| Pain | 9 (26.5) | 25 (33.8) | 37 (43.0) | 0.098 |
| Swelling | 16 (47.1) | 23 (32.1) | 31 (36.0) | 0.275 |
| Fever (≥38.3°C) | 2 (5.9) | 11 (14.9)* | 2 (2.3)* |
|
| Local warmth | 7 (20.6) | 10 (13.5) | 6 (7.0) | 0.094 |
| Joint effusion | 3 (8.8) | 7 (9.5) | 9 (10.5) | 0.956 |
| Wound drainage | 16 (47.1) | 27 (36.5) | 20 (23.3)* |
|
|
| ||||
| Monomicrobial | 17 (50.0)* | 58 (78.4) | 63 (73.3) |
|
| Polymicrobial | 16 (47.1)* | 14 (18.9) | 19 (22.1) |
|
| Culture-negative | 1 (2.9) | 2 (2.7) | 4 (4.7) | 0.877 |
| Time to onset median (p25-p75) | 9 (6.75-11.25) | 30 (18.75-42.0) | 308 (148-607.25) | – |
†Adds up to 191. Three patients had a second episode of FRI at a different anatomical location *Post-hoc testing showed statistically significant difference from the other groups at p < 0.05. p25-p75: 25th and 75th percentile, inter-quartile range.
Figure 1Microbiological etiology of FRI according to time to onset of FRI.
The microbiological etiology of polymicrobial fracture-related infections.
| No. | Fracture type | Pathogen 1 | Pathogen 2 | Pathogen 3 | Pathogen 4 | Pathogen 5 |
|---|---|---|---|---|---|---|
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
|
| ||
|
| Closed |
|
|
| ||
|
| Closed |
|
|
| ||
|
| Closed |
|
|
| ||
|
| Closed |
|
|
| ||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
|
|
| |
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
|
| ||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
| |||
|
| Closed |
|
|
|
| |
|
| Closed |
|
| |||
|
| Open |
|
| |||
|
| Open |
|
|
| ||
|
| Open |
|
|
|
|
|
|
| Open |
|
| |||
|
| Open |
|
|
|
| |
|
| Open |
|
| |||
|
| Open |
|
| |||
|
| Open |
|
| |||
|
| Open |
|
| |||
|
| Open |
|
|
| ||
|
| Open |
|
| |||
|
| Open |
|
| |||
|
| Open |
|
|
*Different strains of same pathogen; S., Staphylococcus; Strep., Streptococcus; C., Cutibacterium.
Figure 2Microbiological epidemiology in mono- and polymicrobial FRIs. CoNS, Coagulase-Negative Staphylococci; GNB, Gram negative bacilli (Enterobacterales and non-fermenting GNB); C. acnes, Cutibacterium acnes; MSSA, methicillin-sensitive Staphylococcus aureus; MSSE, methicillin-sensitive Staphylococcus epidermidis; MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus aureus.
Figure 3Frequency of pathogens isolated per body region. Upper extremity: humerus and forearm; lower extremity: femur, tibia, fibula, patella, ankle and foot. Only two patients suffered an FRI of the axial skeleton, these patients were excluded from visualization in this figure as the percentages would be misleading. The cultured pathogen in the axial FRI group was a S. aureus in one patient and a S. epidermidis in the other.
The association between virulent pathogens in monomicrobial infections and clinical confirmatory signs.
| Virulent pathogen | P-value | ||
|---|---|---|---|
| Yes n (%) | No n (%) | ||
|
| 45 (54.9) | 16 (28.6) |
|
|
| 21 (25.6) | 6 (10.7) |
|
|
| 23 (28.0) | 9 (16.1) | 0.102 |
*Statistically significant at p<0.05.
Figure 4Antimicrobial susceptibility of pathogens in early, delayed and late fracture-related infections. (AMC, Amoxicillin/clavulanic acid; CEP, Cefepime; MEH, Methicillin; MER, Meropenem; PIT, Piperacillin-tazobactam).